Common data elements for clinical research in Friedreich's ataxia

To reduce study start‐up time, increase data sharing, and assist investigators conducting clinical studies, the National Institute of Neurological Disorders and Stroke embarked on an initiative to create common data elements for neuroscience clinical research. The Common Data Element Team developed general common data elements, which are commonly collected in clinical studies regardless of therapeutic area, such as demographics. In the present project, we applied such approaches to data collection in Friedreich's ataxia (FRDA), a neurological disorder that involves multiple organ systems. To develop FRDA common data elements, FRDA experts formed a working group and subgroups to define elements in the following: ataxia and performance measures; biomarkers; cardiac and other clinical outcomes; and demographics, laboratory tests, and medical history. The basic development process included identification of international experts in FRDA clinical research, meeting by teleconference to develop a draft of standardized common data elements recommendations, vetting of recommendations across the subgroups, and dissemination of recommendations to the research community for public comment. The full recommendations were published online in September 2011 at http://www.commondataelements.ninds.nih.gov/FA.aspx. The subgroups′ recommendations are classified as core, supplemental, or exploratory. Template case report forms were created for many of the core tests. The present set of data elements should ideally lead to decreased initiation time for clinical research studies and greater ability to compare and analyze data across studies. Their incorporation into new, ongoing studies will be assessed in an ongoing fashion to define their utility in FRDA. © 2012 Movement Disorder Society

[1]  A. Duhaime,et al.  Common data elements for research on traumatic brain injury: pediatric considerations. , 2012, Journal of neurotrauma.

[2]  Rachel P Berger,et al.  Common data elements for pediatric traumatic brain injury: recommendations from the working group on demographics and clinical assessment. , 2012, Journal of neurotrauma.

[3]  S. Heald,et al.  Use of an Adaptive Study Design in Single Ascending‐Dose Pharmacokinetics of A0001 (α‐Tocopherylquinone) in Healthy Male Subjects , 2012, Journal of clinical pharmacology.

[4]  N. Barbaro,et al.  Common data elements in epilepsy research: Development and implementation of the NINDS epilepsy CDE project , 2011, Epilepsia.

[5]  Henry L. Lew,et al.  Common data elements for traumatic brain injury: recommendations from the interagency working group on demographics and clinical assessment. , 2010, Archives of physical medicine and rehabilitation.

[6]  S. Perlman,et al.  A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. , 2010, Archives of neurology.

[7]  S. Hecht,et al.  Does oxidative stress contribute to the pathology of Friedreich's ataxia? A radical question , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  A. Blamire,et al.  Analysis of the factors influencing the cardiac phenotype in Friedreich's ataxia , 2010, Movement disorders : official journal of the Movement Disorder Society.

[9]  D. Lynch,et al.  Health-related quality of life in children with Friedreich ataxia. , 2010, Pediatric neurology.

[10]  M. Pandolfo,et al.  PGC-1alpha Down-Regulation Affects the Antioxidant Response in Friedreich's Ataxia , 2010, PloS one.

[11]  K. Bushara,et al.  Measuring the rate of progression in Friedreich ataxia: Implications for clinical trial design , 2010, Movement disorders : official journal of the Movement Disorder Society.

[12]  Dagmar Timmann,et al.  Comparison of three clinical rating scales in Friedreich ataxia (FRDA) , 2009, Movement disorders : official journal of the Movement Disorder Society.

[13]  D. Geschwind,et al.  Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARγ pathway as a therapeutic target in Friedreich’s ataxia , 2009, Human molecular genetics.

[14]  K. Fischbeck,et al.  Clinical experience with high-dose idebenone in Friedreich ataxia , 2009, Journal of Neurology.

[15]  Robert B. Wilson,et al.  Pharmacotherapy for Friedreich Ataxia , 2009, CNS drugs.

[16]  T. Ashizawa,et al.  Health related quality of life measures in Friedreich Ataxia , 2008, Journal of the Neurological Sciences.

[17]  W. Poewe,et al.  Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin , 2007, Annals of neurology.

[18]  K. Fischbeck,et al.  Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial , 2007, The Lancet Neurology.

[19]  L. Corben,et al.  Quality of life in Friedreich ataxia: what clinical, social and demographic factors are important? , 2007, European journal of neurology.

[20]  P. Bauer,et al.  Cardiomyopathy in Friedreich's ataxia‐assessment by cardiac MRI , 2007, Movement disorders : official journal of the Movement Disorder Society.

[21]  Nathalie Boddaert,et al.  Selective iron chelation in Friedreich ataxia: biologic and clinical implications. , 2007, Blood.

[22]  S. Perlman,et al.  Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia , 2006, Nature chemical biology.

[23]  J. Hobart,et al.  International cooperative ataxia rating scale (ICARS): Appropriate for studies of Friedreich's ataxia? , 2005, Movement disorders : official journal of the Movement Disorder Society.

[24]  L. Balcer,et al.  Performance measures in Friedreich ataxia: Potential utility as clinical outcome tools , 2005, Movement disorders : official journal of the Movement Disorder Society.

[25]  L. Balcer,et al.  Contrast Letter Acuity as a Measure of Visual Dysfunction in Patients with Friedreich Ataxia , 2002, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[26]  L. Balcer,et al.  Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. , 2002, Archives of neurology.

[27]  A. Munnich,et al.  Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia , 1997, Nature Genetics.

[28]  M. Pandolfo,et al.  Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. , 1997, Science.

[29]  I. G. Fantus,et al.  Evidence for abnormal regulation of insulin receptors in Friedreich's ataxia. , 1993, The Journal of clinical endocrinology and metabolism.

[30]  G. Finocchiaro,et al.  Glucose metabolism alterations in Friedreich's ataxia , 1988, Neurology.

[31]  I. G. Fantus,et al.  Glucose intolerance in Friedreich's ataxia: association with insulin resistance and decreased insulin binding. , 1986, Metabolism: clinical and experimental.

[32]  A. Harding Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. , 1981, Brain : a journal of neurology.